生命科学资讯
生物技术与制药领域的最新动态
Solid Biosciences gets $240M for pipeline; Roche expounds on lupus data
Post-Hoc Live: What will the US government do about China biotech?
Pfizer gets obesity drug approval in China shortly after buying local rights
Lilly plucks Flagship, bluebird vet for regenerative medicine unit; Novo's new China president
FDA官员质疑顾问委员会的必要性
FDA official questions need for advisory committees
Kura称其menin抑制剂获部分支付方青睐成为首选疗法
Kura says its menin inhibitor is preferred treatment for some payers
罗氏合作伙伴Zealand公布胰淀素肥胖药物二期试验数据
Roche partner Zealand posts Phase 2 data for amylin obesity drug
罗氏、Element与Ultima共同推进100美元基因组测序目标
Roche, Element and Ultima push toward the $100 genome
FDA批准强生多发性骨髓瘤组合疗法作为二线治疗方案。
FDA approves J&J's multiple myeloma combo as second-line treatment
赫鲁斯制药股价因迷幻药剂量数据受质疑而下滑。
Helus Pharma's stock slides after psychedelic drug data face questions over dosing
FDA新奖金试点计划应对“人力挑战”
New FDA bonus pilot to address 'workforce challenges'
礼来新计划旨在提升雇主对GLP-1药物的保险覆盖
Eli Lilly's new program aims to boost employer coverage of GLP-1s
Tenaya与Alnylam达成心血管疾病合作协议
Tenaya wins support from Alnylam in cardio disease pact
旧金山健康人工智能快讯
Health AI dispatch from SF
中国挑战全球十大最昂贵药品
China is taking on the world’s 10 most expensive medicines
默克集团放弃SpringWorks交易中两项癌症试验资产。
Merck KGaA drops two cancer trials on assets from SpringWorks deal
诺和诺德详述爱尔兰扩张计划；EuroAPI的挑战持续存在
Novo Nordisk details Irish expansion; EuroAPI’s challenges continue
医院如何从AI实验转向成本合理化
How hospitals have shifted from experimenting with AI to justifying its cost
耶鲁大学克雷格·克鲁斯构建模型，助力生物科技初创企业跨越学术“死亡谷”。
Yale’s Craig Crews builds model to guide biotech startups out of academia’s ‘valley of death’